Vaginismus

Seeking Participants to Advance Research on Vaginismus and Related Painful Sex MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Materna Medical, Inc., a leading innovator in women's pelvic health solutions, is proud to announce the launch of a new clinical study, Prospective On Market Patient-reported Outcomes for Milli™ Vaginal Dilator (POMPOM). This groundbreaking clinical investigation aims to gather valuable data on the effectiveness of the Milli Vaginal Dilator to help relieve the symptoms of vaginismus and related painful intercourse. Millions of People Are Affected by Vaginismus Vaginismus is a common yet underreported condition affecting between 5-17% of people assigned female at birth. The condition is characterized by involuntary muscle contractions of the vaginal wall, making sexual penetration difficult or impossible. Many suffer in silence because they are not aware that vaginismus is a treatable medical condition and don’t realize that help is available. "Treatments for male sexual dysfunction are well-funded and well-researched, but there is a critical lack of research on medical interventions for vaginismus and related painful sex," says Tracy MacNeal, CEO of Materna Medical. "The POMPOM study will generate essential data on the Milli Vaginal Dilator, a discrete, convenient, at-home solution for managing this common condition." Materna’s Solution for Vaginismus The Milli Vaginal Dilator, our first product, addresses this condition to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance* to sell over the counter, enabling streamlined access to people suffering from vaginismus. Seeking Participants to Drive Research Forward Materna Medical invites people experiencing vaginismus symptoms to participate in the POMPOM study (ClinicalTrials.gov NCT06397885). The virtual, secure, confidential format allows convenient participation and makes research accessible to a broader population. “By participating in this study, Milli users will help clinicians learn more about how to help women with vaginismus and associated painful intercourse,” said Sheryl Kingsberg, Ph.D., Professor, Departments of Reproductive Biology, Psychiatry, and Urology, Case Western Reserve University School of Medicine and POMPOM’s Principal Investigator. “Treatment for this debilitating problem remains underutilized though technological advances in pharmacology and devices, like the Milli Vaginal Dilator, may help in alleviating the painful symptoms associated with vaginismus.” The POMPOM study builds on the initial Milli Vaginal Dilator data previously published in the April 2021 issue of Sexual Medicine Reviews, Vaginal Dilators: Issues and Answers.1 For more information on POMPOM Study selection criteria and compensation, please visit info.hellomilli.com/pompom. About Materna Medical Materna Medical is a novel OBGYN platform company defining a $6B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical’s mission is to empower women to protect their pelvic health. Materna’s second product, Materna Prep, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial running in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms. *Indication Statement: The Milli Vaginal Dilator is a tool intended for controlled dilation of the vagina. It can be used for dilation for an examination, in preparation for a surgical procedure, or to help relieve the symptoms of vaginismus (condition that involves tightening of the vaginal muscles) and related painful sex. 1Liu M, Juravic M, Mazza G, Krychman ML. Vaginal Dilators: Issues and Answers. Sex Med Rev. 2021 Apr;9(2):212-220. doi: 10.1016/j.sxmr.2019.11.005. Epub 2020 Jan 31. PMID: 32014450.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Materna Medical, Inc., a leading innovator in women's pelvic health solutions, has announced the completion of the first close of a $20 million Series B2 financing round. The round was led by InnovaHealth Partners and other key existing investors included Wavemaker Three-Sixty Health, Kimera Limited, Women's Venture Capital Fund, Golden Seeds, Band of Angels, and Houston Angel Network. "Materna is a first mover, aiming to transform the standard of care in labor and delivery. Imagine a world in which women aren’t injured while delivering vaginally," commented Tracy MacNeal, Chief Executive Officer for Materna Medical. "Our nation’s maternal health crisis is a clarion call for new obstetrical technologies, and Materna is leading the way." The company has successfully reached several key milestones, including obtaining over-the-counter FDA clearance for its first commercial product, the Milli Vaginal Dilator. Additionally, clinical data from an expanded feasibility study of Materna’s second product, Materna Prep, shows substantial promise in the potential to reduce pelvic floor injury rates for women delivering vaginally. Dr. Ariella Golomb, Materna’s Board Chair and Partner at InnovaHealth Partners added, "We are pleased with the Company’s progress, excited about the feasibility data and look forward to its publication later this year. The funds from Series B2 will be used to obtain FDA marketing authorization for Materna Prep and support the commercial launch of this transformative technology.” For more information on Materna Medical, visit MaternaMedical.com. About Materna Medical Materna Medical is a novel OBGYN platform company defining a $6B market with core technologies addressing unmet needs in women's pelvic health. With headquarters in Mountain View, California, Materna pulls from the top minds in MedTech to truly transform the standard of care in OBGYN. With a diverse team of engineers, scientists, researchers, and commercial leaders, Materna Medical’s mission is to empower women to protect their pelvic health. Our first product, Milli, is vaginal dilator to support patients suffering from vaginismus and related painful sex. In 2019, the Milli device launched as a wellness trainer and, in 2023, received FDA clearance to sell over the counter, enabling streamlined access to people suffering from vaginismus. Milli outcomes are being studied in a post-market prospective virtual study named POMPOM. Materna’s second product, Materna Prep, is an investigational device used during labor and is intended to reduce pelvic floor muscle injury during vaginal delivery. This product is being studied in the EASE trial, a large, randomized controlled trial running in 20 top US hospitals. Materna aims to transform the standard of care in labor and delivery by protecting pelvic floor health for moms.

Dr. Amyas Kabir pioneering two revolutionary procedures to build and strengthen muscles. BLOOMINGTON, Ill., Oct. 12, 2023 /PRNewswire/ -- In his goal of providing superb chiropractic care, clinical excellence and personal touch, renowned chiropractor and director of the Kabir Center for Health, Amyas Kabir, D.C., is one of the first in Central Illinois to offer two leading-edge procedures using electromagnetic energy for patients wanting to build and strengthen muscles. He will highlight these new technologies during a grand re-opening of the center on Oct. 19. Those who want to eliminate excess fat cells can benefit from EmSculpt Neo, a non-invasive procedure using electromagnetic energy and radiofrequency forcing muscles to contract -- ultimately sculpting areas of the body, including abdomen, buttocks, arms, calves, and thighs. The FDA-cleared needle- and laser-free device forces muscles to experience tens of thousands of contractions in just a 30-minute session, like doing 20,000 sit-ups. Four treatments of EmSculpt Neo are equivalent to 12 to 16 weeks of a high intensity interval training (HIIT) program. With over 25 million adult Americans experiencing some form of urinary incontinence, Dr. Kabir's other new technology is a windfall for women struggling with urinary incontinence and pelvic floor weakness. EMSELLA is a revolutionary chair that essentially strengthens the pelvic floor by inducing muscle contractions. Fully clothed patients sit in the EMSELLA chair for the noninvasive procedure that uses electromagnetic energy to stimulate and strengthen the pelvic floor muscles. Each 30-minute session is equivalent to 11,000 pelvic floor exercises (Kegel exercises). Stronger pelvic floor muscles restore continence and the confidence to enjoy normal daily activities without fear of losing bladder control. With no down-time needed, patients can immediately resume normal daily activities. Dr. Kabir recommends patients do six treatments over three weeks for maximum results. "It is heartening to witness the vast improvements in quality of life offered by the EmSculpt Neo and EMSELLA," says Dr. Kabir. "I'm thrilled to be able to provide these groundbreaking technologies to my patients." People who want to learn more about these leading-edge, non-invasive technologies are invited to attend the grand re-opening of the newly renovated, warm, and inviting Kabir Center for Health, 2412 E. Washington St., Bloomington, IL., 4:30 – 7 p.m., Thursday, Oct. 19. Attendees will have an opportunity to tour the center, learn about services offered, and sign up for demonstrations of the new technology. They will be treated to refreshments, appetizers and are eligible for raffle prizes. Amyas Kabir, D.C Dr. Kabir has been in practice in Bloomington, Illinois for over 25 years and is an expert in the field of human health & wellness. His mission is to provide his patients and community with the tools to maximize their regenerative and restorative potential. He takes pride in providing patients with best possible outcomes. To learn more about Dr. Kabir, log on to kabircenter4health.com. SOURCE Kabir Center for Health